Trial · NCT05183204
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
NCT05183204, Phase 2, Completed, Weill Medical College of Cornell University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma. Trials, record NCT05183204. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05183204
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
- NCT number
- NCT05183204
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 24 participants, actual
- Lead sponsor
- Weill Medical College of Cornell University
- Conditions
- Glioblastoma
- Interventions
- Paxalisib, Metformin, Ketogenic Diet
- First posted
- 2022-01-10
- Last updated
- 2026-09-25
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival, defined as the survival rate at 6 months | At 6 months after the start of study treatment | Measured by the occurrence of a progression event as per RANO criteria or death due to any cause prior to 6 months |
| Secondary | Overall survival, defined as the time of first study treatment to death from any cause | From the start of study enrollment until death, up to approximately 18 months | |
| Secondary | Change in insulin levels | From baseline assessments through 8 weeks post-treatment | Evaluated by the mean and standard deviation of values over time |
| Secondary | Change in tumor glucose uptake values | From baseline assessments through 8 weeks post-treatment | Measured by FDG-PET/DCE MRI |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05183204
GET https://conductscience.org/api/trials/v1/NCT05183204/registered